ClinicalTrials.gg
Active, not recruitingNCT06513832Updated Nov 13, 2026

Asthma Navigator Intervention to Improve Health Equity in Children

An interventional study of The asthma navigator in Asthma in Children, sponsored by Emory University. Active, not recruiting at 1 site in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Emory University · Not applicable, Interventional, and Prevention

How we know

Updated Nov 13, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Asthma by Emory University — none open to participants now, 1 under way, none of them phase 3. Asthma · Emory University.

Started
2025
with 1 other
No phase
2 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Asthma by Emory University, this one is one of 2 that started in 2025, is one of 2 with no phase, and was the 10th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 11 studies in Asthma by Emory University is open now. The open studies under Asthma, anywhere →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Asthma by Emory University as a file.
02

Study summary

The goal of this study is to improve health equity in children aged 5-16.9 years admitted to the PICU for asthma. The objectives are:

  • To identify the factors related to differential experiences of asthma self-management
  • To pilot the effectiveness of an individualized asthma navigator intervention at PICU discharge.
Read the detailed description

Despite available asthma treatments, nearly 50% of children with asthma experience exacerbations annually, with disadvantaged children, particularly Black and Hispanic, being the most affected. These disparities are largely due to social determinants of health (SDOH), including socioeconomics and family hardship, which explain over 80% of the racial disparities in asthma outcomes. Children in lower opportunity neighborhoods face additional challenges like poor housing and limited green spaces, increasing exposure to pollutants and allergens.

At Children's Healthcare of Atlanta's Pediatric ICU (PICU), 85% of asthma admissions come from low-opportunity areas, with 36.7% having another exacerbation within a year. Significant barriers to better outcomes include limited provider understanding of SDOH and challenges in asthma self-management. Effective asthma self-management, supported by medical providers, is crucial for improving health outcomes in these disadvantaged children.

03

Conditions studied

  • Asthma in Children

Browse trials for

Keywords

  • Asthma self-management
  • Asthma in Children
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to the PICU for asthma

Exclusion criteria

Exclusion Criteria:

  • Cystic fibrosis
  • Immune deficiency
  • Prematurity \<35 weeks
  • Gestation and congenital airway deformities
  • Non-English speaker
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    The Asthma Navigator

    The Children's electronic medical record (EMR) of each child will be screened weekly for up to 52 weeks. When an asthma exacerbation prompting unscheduled healthcare utilization is noted (primary outcome), or at the end of 52 weeks, participant involvement in the study will end.

    Behavioral: The asthma navigator

  • No intervention
    Standard of Care

    This arm will not have access to the Asthma Navigator. The Children's EMR of each child will be screened weekly for up to 52 weeks. When an asthma exacerbation prompting unscheduled healthcare utilization is noted (primary outcome), or at the end of 52 weeks, participant involvement in the study will end.

Interventions

  • BehavioralThe asthma navigator

    The asthma navigator is a Registered Respiratory Therapist and Certified Asthma Educator who will review the care plan at discharge and provide asthma education; assist with follow-up clinic appointment scheduling, medication access, and transportation; and daily as-needed telephone support.

06

What researchers measure

Primary outcomes

  1. Future unscheduled healthcare utilization for asthma exacerbation

    The occurrence of unscheduled healthcare utilization and the date and time of occurrence will be assessed through weekly screenings of each child's EMR at Children's (Epic system).

    Time frame: Baseline, end of study (average of 52 weeks)

Other outcomes

  1. Hospitalization occurrence

    Number of hospitalizations would be measured.

    Time frame: Baseline, end of study (average of 52 weeks)

  2. Clinic follow-up

    Number of clinic follow ups would be measured.

    Time frame: Baseline, end of study (average of 52 weeks)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All subject-level clinical data at enrollment will be preserved and shared during study completion on 7/31/26. Shared data will be deidentified and original data maintained at the Principal Investigator's institution. Recruitment progress and final study results will be documented at clinicaltrials.gov. Protocols, informed consent forms to participate in the trial and the data dictionary will be shared with the data. Data will be shared with qualified investigators with an appropriate research and approved data use agreement (DUA). Data will be accessed by restricted download once approved.

Supporting information: Study protocol, Informed consent form

Time frame: At the time of study completion on August 2026

Access criteria: Data will be accessed by restricted download once approved.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 25 months is close to that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Aug 2026 → Feb 2027 and completion Aug 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 22, 2024
StartActual
Jan 17, 2025
Primary completionEst.
Feb 2027was Aug 2026
CompletionEst.
Jun 2027was Aug 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Feb 2027
Nov 13, 2026
Study completion
Aug 2026→Jun 2027
Nov 13, 2026
Enrollment
75 (estimated)→68 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Primary completion Aug 2026→Feb 2027
    Study completion Aug 2026→Jun 2027
    Enrollment 75 (estimated)→68 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06513832
Lead sponsor
Emory University
Collaborators
Georgia Clinical & Translational Science Alliance
Responsible party
Anne M Fitzpatrick (Assistant Professor, Emory University) — Principal investigator
First posted
Jul 22, 2024
Start date
Jan 17, 2025
Primary completion
Feb 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Anne Fitzpatrick, PhD, APRN
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion